Cargando…
Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of sympt...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498763/ https://www.ncbi.nlm.nih.gov/pubmed/37711206 http://dx.doi.org/10.3389/fonc.2023.1195759 |
_version_ | 1785105587999080448 |
---|---|
author | Couto, Samuel C. F. Kowes, Ariel Aurabi, Camila S. Oliveira, Theo G. M. Klinger, Paulo Rocha, Vanderson |
author_facet | Couto, Samuel C. F. Kowes, Ariel Aurabi, Camila S. Oliveira, Theo G. M. Klinger, Paulo Rocha, Vanderson |
author_sort | Couto, Samuel C. F. |
collection | PubMed |
description | Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of symptoms. PTCLs are often difficult to diagnose and treat, and they have a poorer prognosis than other types of lymphoma. However, recent advancements in treatment options, such as targeted therapies have shown promise in improving outcomes for patients with PTCL. Here, we discuss the use of autologous and allogeneic hematopoietic cell transplantation (HCT) as a treatment strategy for patients with PTCL, as well as the recent treatment approaches based on advanced cellular therapy. The current evidence for the use of HCT in PTCL is mainly derived from registry data, retrospective studies, and expert opinion, as randomized trials are limited due to the low incidence and histological heterogeneity of PTCL subtypes. |
format | Online Article Text |
id | pubmed-10498763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104987632023-09-14 Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? Couto, Samuel C. F. Kowes, Ariel Aurabi, Camila S. Oliveira, Theo G. M. Klinger, Paulo Rocha, Vanderson Front Oncol Oncology Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of symptoms. PTCLs are often difficult to diagnose and treat, and they have a poorer prognosis than other types of lymphoma. However, recent advancements in treatment options, such as targeted therapies have shown promise in improving outcomes for patients with PTCL. Here, we discuss the use of autologous and allogeneic hematopoietic cell transplantation (HCT) as a treatment strategy for patients with PTCL, as well as the recent treatment approaches based on advanced cellular therapy. The current evidence for the use of HCT in PTCL is mainly derived from registry data, retrospective studies, and expert opinion, as randomized trials are limited due to the low incidence and histological heterogeneity of PTCL subtypes. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10498763/ /pubmed/37711206 http://dx.doi.org/10.3389/fonc.2023.1195759 Text en Copyright © 2023 Couto, Kowes, Aurabi, Oliveira, Klinger and Rocha https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Couto, Samuel C. F. Kowes, Ariel Aurabi, Camila S. Oliveira, Theo G. M. Klinger, Paulo Rocha, Vanderson Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? |
title | Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? |
title_full | Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? |
title_fullStr | Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? |
title_full_unstemmed | Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? |
title_short | Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL? |
title_sort | autologous, allogeneic hematopoietic cell transplantation and car-t/nk therapy: what is their real importance in ptcl? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498763/ https://www.ncbi.nlm.nih.gov/pubmed/37711206 http://dx.doi.org/10.3389/fonc.2023.1195759 |
work_keys_str_mv | AT coutosamuelcf autologousallogeneichematopoieticcelltransplantationandcartnktherapywhatistheirrealimportanceinptcl AT kowesariel autologousallogeneichematopoieticcelltransplantationandcartnktherapywhatistheirrealimportanceinptcl AT aurabicamilas autologousallogeneichematopoieticcelltransplantationandcartnktherapywhatistheirrealimportanceinptcl AT oliveiratheogm autologousallogeneichematopoieticcelltransplantationandcartnktherapywhatistheirrealimportanceinptcl AT klingerpaulo autologousallogeneichematopoieticcelltransplantationandcartnktherapywhatistheirrealimportanceinptcl AT rochavanderson autologousallogeneichematopoieticcelltransplantationandcartnktherapywhatistheirrealimportanceinptcl |